Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jilixin
- Development stage
- Unknown
- Lead developer
- Jiuyuan Gene Engineering
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Jilixin (avatrombopag) is an oral, small-molecule thrombopoietin (TPO) receptor agonist developed and manufactured by Hangzhou Jiuyuan Gene Engineering. It functions by binding to the transmembrane domain of the TPO receptor (MPL) on megakaryocytes and their progenitor cells, stimulating their proliferation and differentiation into platelets. This mechanism effectively increases platelet counts in patients with thrombocytopenia. Jilixin is approved in China for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a medical or dental procedure, as well as for adult patients with chronic primary immune thrombocytopenia (ITP) who have shown an inadequate response to previous therapies. As an oral medication, it offers a non-invasive alternative to injectable TPO receptor agonists, improving patient convenience and compliance.
- Brand names
- Jilixin吉立欣
- Other names
- avatrombopagavatrombopag maleate阿伐曲泊帕
02
Targets
TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on Jilixin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jilixin.